Novartis to give prior notice for domestic introduction of Entresto
‘Entresto,’ a Novartis’s new cardiac insufficiency drug, will be introduced in Korea.
According to the industry concerned on the 16th, Novartis has applied for the domestic approval of Entresto, a valsartan+sacubitril cardiac insufficiency treatment, which has lately been called as ‘LCZ696.’
Wh...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
